December 17, 2019 10:01 AM EST

Biohaven celebrates PhII/III win for intranasal CGRP migraine drug amid oral race with Allergan

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact